Sign in
IMV Stock Price, Chart, Stats & News
IMV Inc.
Save
9.63M
Market cap
–
Current P/E
–
Forward P/E
IMV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -1.32% |
ROA | -122.79% |
ROE | -515.29% |
D/E | -4.38x |
Interest coverage ratio | -78.83x |
IMV valuation
P/E | – |
P/S | – |
P/B | -1.04x |
P/CF | -0.21x |
P/FCF | -0.28x |
P/OCF | -0.21x |
PEG | -0.00x |
EV multiple | -0.05x |
About
IMV Inc., a clinical-stage biotechnology company founded in 2000 and based in Dartmouth, Canada, is focused on immuno-oncology. The firm develops a range of therapeutic candidates for solid and hematological cancers utilizing its proprietary DPX immune-educating technology platform. Its primary drug candidate, maveropepimut-S, is a DPX-based immunotherapy engineered to specifically target survivin-expressing cells.
Similar securities
Based on sector and market capitalization
Report issue